{
    "ticker": "CELC",
    "name": "Celcuity Inc.",
    "description": "Celcuity Inc. is a biotechnology company focused on discovering and developing personalized cancer therapies through its proprietary Celcuity platform. Founded in 2012 and headquartered in Minneapolis, Minnesota, Celcuity aims to transform the treatment of cancer by tailoring therapies to the unique molecular characteristics of each patient's tumor. The company's innovative approach leverages its expertise in cell biology and oncology to identify biomarkers that can predict which patients will respond best to specific treatments. Celcuity's lead product candidate, the investigational drug CYC140, is designed to target certain cancer types, particularly those with specific genetic mutations. By utilizing the Celcuity platform, the company seeks to enhance the efficacy of cancer treatments and improve patient outcomes. Additionally, Celcuity is committed to advancing the understanding of cancer biology and the development of new therapeutic strategies. With a focus on precision medicine, Celcuity is positioned at the forefront of the fight against cancer, striving to bring hope to patients through its scientific innovations.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Minneapolis, Minnesota, USA",
    "founded": "2012",
    "website": "https://www.celcuity.com",
    "ceo": "Brian Sullivan",
    "social_media": {
        "twitter": "https://twitter.com/Celcuity",
        "linkedin": "https://www.linkedin.com/company/celcuity/"
    },
    "investor_relations": "https://ir.celcuity.com",
    "key_executives": [
        {
            "name": "Brian Sullivan",
            "position": "CEO"
        },
        {
            "name": "David M. Fink",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Treatments",
            "products": [
                "CYC140"
            ]
        }
    ],
    "seo": {
        "meta_title": "Celcuity Inc. | Personalized Cancer Therapies",
        "meta_description": "Explore Celcuity Inc., a biotechnology company focused on personalized cancer therapies. Learn about its innovative Celcuity platform and lead product candidate CYC140.",
        "keywords": [
            "Celcuity",
            "Cancer Therapy",
            "Biotechnology",
            "Personalized Medicine",
            "CYC140"
        ]
    },
    "faq": [
        {
            "question": "What is Celcuity focused on?",
            "answer": "Celcuity is focused on developing personalized cancer therapies using its proprietary Celcuity platform."
        },
        {
            "question": "Who is the CEO of Celcuity?",
            "answer": "Brian Sullivan is the CEO of Celcuity Inc."
        },
        {
            "question": "Where is Celcuity headquartered?",
            "answer": "Celcuity is headquartered in Minneapolis, Minnesota, USA."
        },
        {
            "question": "What is Celcuity's lead product candidate?",
            "answer": "Celcuity's lead product candidate is CYC140, aimed at targeting specific cancer types."
        },
        {
            "question": "When was Celcuity founded?",
            "answer": "Celcuity was founded in 2012."
        }
    ],
    "competitors": [
        "CLVS",
        "KITE",
        "IMMU",
        "ALNY"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "GILD",
        "MRNA"
    ]
}